VELCADE

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug VELCADE contains one active pharmaceutical ingredient (API):

1 Bortezomib
UNII 69G8BD63PP - BORTEZOMIB

Bortezomib is a proteasome inhibitor. It is specifically designed to inhibit the chymotrypsin-like activity of the 26S proteasome in mammalian cells. Inhibition of the 26S proteasome prevents this targeted proteolysis and affects multiple signalling cascades within the cell, ultimately resulting in cancer cell death.

Read about Bortezomib

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
VELCADE Powder for solution European Medicines Agency (EU) MPI, EU: SmPC
Velcade 3.5 mg powder for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01XG01 Bortezomib L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XG Proteasome inhibitors
Discover more medicines within L01XG01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 12219D, 12227M
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 514506401156317
Country: CA Health Products and Food Branch Identifier(s): 02262452
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 27.605-1-03-12
Country: EE Ravimiamet Identifier(s): 1148004, 1364868
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 04274001
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 017195
Country: FR Base de données publique des médicaments Identifier(s): 62438913, 69756861
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 75131
Country: HK Department of Health Drug Office Identifier(s): 60429, 63741
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 4829
Country: JP 医薬品医療機器総合機構 Identifier(s): 4291412D1024
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1031151, 1032114
Country: MX Comisión Federal para la Protección contra Riesgos Sanitarios Identifier(s): 654M2004
Country: NL Z-Index G-Standaard, PRK Identifier(s): 75299, 93610
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 11690, 13403
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100085192, 100194113
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W42249001, W53033001
Country: SG Health Sciences Authority Identifier(s): 13064P
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 15273011H
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699593775017
Country: US FDA, National Drug Code Identifier(s): 63020-049
Country: ZA Health Products Regulatory Authority Identifier(s): 43/26/0427, A40/26/0005

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.